26
Participants
Start Date
December 31, 2016
Primary Completion Date
June 30, 2020
Study Completion Date
August 31, 2020
Extended release morphine
Dose (tailored to each participant based on his/her pre-experimental opioid use amount) is administered in 3 divided daily doses.
Buprenorphine/Naloxone low dose
Buprenorphine/Naloxone dose of 1.4/0.36 mg/day
Buprenorphine/Naloxone moderate dose
Buprenorphine/Naloxone dose of 4.2/1.08 mg/day
Buprenorphine/Naloxone high dose
Buprenorphine/Naloxone dose of 12.8/3.16 mg/day
Active stressor
Yohimbine hydrochloride 60mg + Hydrocortisone 20mg tablet
Placebo stressor
Lactose
Vince and Associates, Overland Park
Wayne State University
OTHER